DXB
DIMERIX FPO [DXB]
Healthcare · ASX Small Cap
$0.3250 +0.0%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical45
Catalyst56
Sentiment50
Fundamental82
Momentum43
Risk Gate50
Get alerts when DXB's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Stochastic is deep in oversold territory — bounce conditions forming
- Lagging the Small Ords index — relative strength of 0.76, underperforming its peers
- Cash positive / operating cashflow positive
- Strong revenue growth (+636%)
- EPS estimates revised upward (+10pts)
- Near 52-week low (1% of range)
- Sentiment is mixed — no strong consensus either way
- Revenue growing at +636% — the top line is moving in the right direction
- Beneish M-Score 7.74 > -1.78: likely earnings manipulation
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Deeply negative margins (-220%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- The bigger volume days are the down days — volume-weighted momentum is negative (-1.43%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about DXB
3 free messages/day · Unlimited with Pro
Recent Catalysts
LOW Dimerix Presents at Euroz Hartleys Institutional Conference
LOW Dimerix Presents at Oppenheimer Life Sciences Conference
NONE Dimerix to Conduct Review of ACTION3 Statistical Assumptions
NONE Dimerix Invitation to Perth and Singapore Investor Briefings
HIGH Dimerix Phase 3 Trial Last Patient Receives First Dose
Recent ASX Announcements
| 2026-03-15 | Dimerix Presents at Euroz Hartleys Institutional Conference |
| 2026-03-15 | Dimerix to Conduct Review of ACTION3 Statistical Assumptions PRICE SENSITIVE |
| 2026-03-09 | Dimerix Phase 3 Trial Last Patient Receives First Dose PRICE SENSITIVE |
| 2026-03-03 | Dimerix Invitation to Perth and Singapore Investor Briefings |
| 2026-02-26 | Dimerix Presents at Oppenheimer Life Sciences Conference |
Key Metrics
$195.1M
Market Cap
1.2M
Avg Volume
0.7x
Vol Ratio
$0.32 — $0.79
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-594.5%
ROE
-219.9%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 78% |
| L | Leader vs Laggard | laggard | RS: -9 |
| I | Institutional Sponsorship | weak | Inst: 1% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #104 of 117 · Sector avg: 46
View all Healthcare signals →Track DXB and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required